Search clinical trials for: tumor mutation burden

Total 35883 results

IRCCS Eugenio Medea

Recruiting

Eye Movement Desensitization and Reprocessing Group Treatment for Caregivers of Pediatric Brain Tumor Patients

Caregiver Burden

Italy
Washington University School of Medicine
National Cancer Institute (NCI); The Foundation for Barnes-Jewish Hospital

Recruiting

Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)

Multiple Myeloma | Rectal Cancer | Cholangiocarcinoma | Colon Cancer

United States
National Cancer Institute (NCI)

Not yet recruiting

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

Classic Follicular Lymphoma | Follicular Lymphoma With Unusual Cytological Features
Institut Curie
Merck Sharp & Dohme LLC; ProLynx LLC

Not yet recruiting

A Study on Tuvusertib (Oral ATR Inhibitor) in Combination With PLX038 (Topo1 Inhibitor) in Patients With Advanced Solid Tumors (POP-ART)

Solid Tumor

France
Nested Therapeutics, Inc

Recruiting

A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors (NST-628)

Glioma | Melanoma | NSCLC | Oncology | Solid Tumor, Adult | MEK Mutation | RAF Gene Mutation | Ras (KRAS or NRAS) Gene Mutation | MAPK Pathway Gene Mutation

United States, Australia
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure

Non Small Cell Lung Cancer

China
Pasithea Therapeutics Corp.

Recruiting

PAS-004 in Patients With Advanced Solid Tumors

Advanced Solid Tumors | RAS Mutation | NF1 Mutation | RAF Mutation

United States
Liaoning Tumor Hospital & Institute

Not yet recruiting

Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene Mutations

Non Small Cell Lung Cancer
Deciphera Pharmaceuticals LLC

Recruiting

Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway

Melanoma | Non-Small Cell Lung Cancer | Advanced Solid Tumor | Pancreatic Ductal Adenocarcinoma | BRAF Gene Mutation | RAS Mutation | NF1 Mutation | RAF Mutation | CRAF Gene Mutation

United States
Ikena Oncology

Recruiting

Study of IK-595 in RAS- or RAF-altered Advanced Tumors

Colorectal Cancer | Pancreatic Cancer | Thyroid Carcinoma | Solid Tumor, Adult | Malignant Melanoma | Non-Small Cell Lung Carcinoma | BRAF Gene Mutation | Gliomas, Malignant | Ras (Kras or Nras) Gene Mutation | CRAF Gene Mutation

United States
Shandong University

Not yet recruiting

Exploration of Fenestration Decompression Combined With Dalafenib in the Treatment of BRAF Mutant Ameloblastoma

Ameloblastoma
Novartis Pharmaceuticals

Recruiting

Special Drug Use-results Surveillance of Tafinlar/Mekinist

BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor

Japan
Technische Universität Dresden
Universitätsmedizin Mannheim; SOS Desmoid e.V.

Recruiting

Burden of Disease and Living Situation in Desmoid Patients (PROSa Desmoid)

Quality of Life | Desmoid Tumor

Germany
National Cancer Institute (NCI)

Recruiting

Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer

Breast Cancer | Colorectal Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Gastrointestinal Cancer | Genitourinary Cancer | Metastatic Solid Cancers

United States
Iambic Therapeutics, Inc

Recruiting

A Phase 1/1b Study of IAM1363 in HER2 Cancers

HER2 Mutation-Related Tumors

United States
Sichuan Huiyu Pharmaceutical Co., Ltd

Recruiting

Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation

Efficacy | Tolerability | Safety

China
Frontier Medicines Corporation

Recruiting

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors (PROSPER)

Colorectal Cancer | Pancreatic Cancer | Non Small Cell Lung Cancer | Metastatic Solid Tumor | Solid Tumor, Adult | Unresectable Solid Tumor | KRAS G12C | Advanced Solid Tumors With KRAS G12C Mutations

United States
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Recruiting

A Study of ZG2001 in Participants With KRAS Mutated Advanced Solid Tumours

Solid Tumor | KRAS Mutation-Related Tumors

China
N.N. Petrov National Medical Research Center of...

Recruiting

Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations (NТО-RAS)

Melanoma | Lung Cancer | Pancreas Cancer | Refractory Cancer | Colorectal Cancer Recurrent | RAS Mutation | Ras (Kras or Nras) Gene Mutation

Russian Federation
Quanta Therapeutics

Recruiting

QTX3034 in Patients With KRAS G12D Mutation

Solid Tumors

United States
Neogene Therapeutics, Inc.

Recruiting

A Study of NT-112 in HLA-C*08:02-Positive Adult Subjects With Unresectable, Advanced, and/ or Metastatic Solid Tumors Positive for the KRAS G12D Mutation

Endometrial Cancer | Non-small Cell Lung Cancer | Pancreatic Ductal Adenocarcinoma | Colorectal Carcinoma | Solid Tumor, Adult | KRAS G12D

United States
Sarcoma Alliance for Research through Collaboration
Dana-Farber Cancer Institute; Cogent Biosciences, Inc.; The Life Raft Group

Not yet recruiting

SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST

Gastrointestinal Stromal Tumors | GIST

United States
IRCCS San Raffaele
Università Vita-Salute San Raffaele

Recruiting

Mechanisms of Somatic Mutation and Tumor Initiation in Pre-malignant Kidney Tubule Cells (SoMuKT)

Carcinoma, Renal Cell | Von Hippel-Lindau Disease

Italy
Sixth Affiliated Hospital, Sun Yat-sen University

Recruiting

Machine Learning Predicts Survival and Mutations in Ovarian Metastases of Colorectal Cancer

Ovarian Metastases of Colorectal Cancer

China
Hideho Okada, MD, PhD
National Cancer Institute (NCI); California Institute for Regenerative Medicine...

Recruiting

Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells

Glioblastoma | Recurrent Glioblastoma | EGFR Gene Mutation | MGMT-Unmethylated Glioblastoma

United States
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations

Non Small Cell Lung Cancer | ERBB2 Mutation-Related Tumors | Disitamab Vedotin | ERBB2 Gene Duplication
Hunan Province Tumor Hospital

Recruiting

A Real-World Study of Treatment Patterns and Effectiveness in MET Mutation-Positive Advanced Lung Cancer

Advanced Lung Cancer

China
Incyte Corporation

Recruiting

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

Solid Tumors

United States, France, Italy, Australia, Spain, Canada, Belgium
National Cancer Institute (NCI)

Recruiting

Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors

Locally Advanced Chondrosarcoma | Metastatic Chondrosarcoma | Metastatic Sinonasal Adenocarcinoma | Locally Advanced Sinonasal Adenocarcinoma | Metastatic Large-cell Neuroendocrine Carcinoma | Locally Advanced Large-cell Neuroendocrine Carcinoma | Metastatic Olfactory Neuroblastoma | Locally Advanced... and other conditions

United States
Pamela Munster
National Cancer Institute (NCI)

Recruiting

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

BRCA1 Mutation | BRCA2 Mutation | PALB2 Gene Mutation | ATM Gene Mutation | BRCA Mutation | Checkpoint Kinase 2 Gene Mutation

United States
Revolution Medicines, Inc.

Recruiting

Study of RAS(ON) Inhibitor Combinations in Patients With Advanced RAS-mutated NSCLC

Non-Small Cell Lung Cancer, NSCLC | KRAS, NRAS, HRAS-mutated NSCLC | KRAS G12C-mutated Solid Tumors, Lung Cancer | Lung Cancer Stage IV, Advanced Solid Tumor, Cancer

United States
Rigel Pharmaceuticals
Nationwide Children's Hospital

Not yet recruiting

Study of Olutasidenib and Temozolomide in HGG

Astrocytoma | High Grade Glioma | Oligodendroglioma | Diffuse Intrinsic Pontine Glioma | Diffuse Midline Glioma, H3 K27M-Mutant | WHO Grade III Glioma | Metastatic Brain Tumor | Spinal Tumor | Astrocytoma, Grade III | Astrocytoma, Grade IV | IDH1 Mutation | WHO Grade IV Glioma | Thalamus Tumor | IDH1 R132 | IDH1 R132C | IDH1 R132H and other conditions

United States, Australia, United Kingdom, Canada, Germany, Netherlands
Tyra Biosciences, Inc

Recruiting

Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations (SURF201)

Solid Tumor | Intrahepatic Cholangiocarcinoma | Metastatic Cholangiocarcinoma | Locally Advanced Cholangiocarcinoma

United States
International Vaccine Institute
London School of Hygiene and Tropical Medicine; Karolinska Institutet; Centers...

Not yet recruiting

Global Burden Estimation of Human Papillomavirus (GLOBE-HPV) (HPV)

HPV Infection

Zambia, Bangladesh, Congo, The Democratic Republic of the, Ghana, Nepal, Pakistan, Sierra Leone, Tanzania
Revolution Medicines, Inc.

Recruiting

Study of RMC-6291 in Combination With RMC-6236 in Participants With Advanced KRAS G12C Mutant Solid Tumors

Colorectal Cancer | Pancreatic Ductal Adenocarcinoma | Non-Small Cell Lung Cancer (NSCLC)

United States, Puerto Rico
BeBetter Med Inc
Xiangya Hospital of Central South University

Recruiting

Study of BEBT-607 Tablets in The Treatment of Advanced or Metastatic Solid Tumors With KRAS G12C Mutation

Advanced or Metastatic Solid Tumor | KRAS G12C Mutation

China
Hunan Province Tumor Hospital

Recruiting

The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC (PROFILE)

Non Small Cell Lung Cancer | EGF-R Positive Non-Small Cell Lung Cancer | RET Gene Mutation | MET Amplification

China
M.D. Anderson Cancer Center
Bristol-Myers Squibb

Recruiting

Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma

Follicular Lymphoma | Tumor

United States
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of Avutometinib for People With Solid Tumor Cancers

Solid Tumor | Neuroblastoma | Solid Tumor, Adult | Primary Brain Tumor | Solid Carcinoma | Low-grade Glioma | Central Nervous System Tumor | Refractory Cancer | CNS Tumor, Adult | CNS Tumors | NF1 | Plexiform Neurofibroma | CNS Tumor, Childhood | Optic Pathway Gliomas | MAP Kinase Family Gene Mutation

United States
Shanghai YingLi Pharmaceutical Co. Ltd.

Not yet recruiting

Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS

Advanced Solid Tumors

United States
M.D. Anderson Cancer Center
Bayer

Recruiting

Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.

Gastrointestinal Stromal Tumors

United States
Stanford University

Not yet recruiting

Sirolimus for Improving Social Abilities in People With PTEN Germline Mutations

PTEN Gene Mutation | PTEN Hamartoma Tumor Syndrome | PTEN Hamartoma Syndrome

United States
Shanghai YingLi Pharmaceutical Co. Ltd.

Recruiting

A Study of YL-17231 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Hoffmann-La Roche

Recruiting

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

Belgium, Korea, Republic of, United States, Canada, China, Italy, France, Finland, Brazil, Australia, Argentina, Hong Kong, Portugal, Spain, Taiwan, India, Costa Rica, Israel, Thailand, Germany, New Zealand, Poland, Chile, Colombia, Gua... and more
Lebanese University
Haykel Hospital

Recruiting

Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and Polymorphisms (CAT_PB)

Cardiovascular Diseases | Immune System Diseases | Cancer | Breast Cancer | Hepatocellular Carcinoma | Lung Cancer | Chemotherapy | Solid Tumor | Prostate Cancer | Thromboembolism | Colon Cancer | Immunotherapy | Inflammatory Diseases

Lebanon
Boehringer Ingelheim

Recruiting

A Study to Test How Well Different Doses of BI 3706674 Are Tolerated by People With Advanced Cancer in the Stomach and Oesophagus

Solid Tumor, KRAS Mutation

United States, Taiwan, Japan
Children's Oncology Group
National Cancer Institute (NCI)

Recruiting

Somatic Mosaicism in Twins Discordant for Childhood Cancer

Central Nervous System Tumor | Somatic Mutation | Pediatric Central Nervous System Tumor | Discordant Twin

United States
Fred Hutchinson Cancer Center
Affini-T Therapeutics, Inc.

Recruiting

Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Pancreatic, Colorectal and Non-Small Cell Lung Cancers With KRAS G12V Mutations

Metastatic Lung Non-Small Cell Carcinoma | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma | Metastatic Colorectal Adenocarcinoma | Stage IV Lung Cancer AJCC v8 | Stage IV Colorectal Cancer AJCC v8

United States
Incyte Corporation
Mirati Therapeutics Inc.

Recruiting

A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation

Advanced Solid Tumors

United States, Italy, Spain, United Kingdom
European Institute of Oncology
Istituto Oncologico Veneto IRCCS; Ente Ospedaliero Ospedali Galliera; Istituto...

Not yet recruiting

Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion (TOLERANT)

Ductal Carcinoma in Situ | RAD51C Gene Mutation | RAD51D Gene Mutation | PALB2 Gene Mutation | Lobular Carcinoma in Situ | ATM Gene Mutation | CDH1 Gene Mutation | CHEK2 Gene Mutation | BRCA Mutation

Italy

Search clinical trials for: tumor mutation burden

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Venezuela

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations